QUANTRES ASSET MANAGEMENT Ltd lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 291.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 52,800 shares of the biopharmaceutical company’s stock after buying an additional 39,300 shares during the quarter. Gilead Sciences makes up 2.4% of QUANTRES ASSET MANAGEMENT Ltd’s holdings, making the stock its 2nd largest holding. QUANTRES ASSET MANAGEMENT Ltd’s holdings in Gilead Sciences were worth $3,783,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Welch Investments LLC purchased a new position in shares of Gilead Sciences during the 3rd quarter valued at $108,000. Wealthcare Advisory Partners LLC purchased a new position in shares of Gilead Sciences during the 3rd quarter valued at $133,000. Horan Capital Advisors LLC. purchased a new position in shares of Gilead Sciences during the 3rd quarter valued at $144,000. Hanson & Doremus Investment Management lifted its stake in shares of Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 1,613 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at $147,000. Institutional investors own 76.47% of the company’s stock.

Shares of Gilead Sciences, Inc. (GILD) opened at $80.79 on Wednesday. The company has a current ratio of 3.55, a quick ratio of 3.48 and a debt-to-equity ratio of 1.10. The stock has a market cap of $104,684.40, a PE ratio of 9.38, a PEG ratio of -1.83 and a beta of 1.22. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $89.54.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The business’s revenue was down 18.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.70 EPS. sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.24 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 2.82%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is currently 59.77%.

A number of research firms recently weighed in on GILD. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 target price on the stock in a research note on Monday, February 5th. Leerink Swann lifted their target price on shares of Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a research note on Thursday, October 19th. Citigroup reiterated a “buy” rating and issued a $105.00 price target (up previously from $103.00) on shares of Gilead Sciences in a research note on Thursday, February 8th. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $86.00 to $88.00 and gave the stock a “market perform” rating in a research note on Thursday, February 8th. Finally, Mizuho boosted their price target on shares of Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $87.04.

In other news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $74.98, for a total transaction of $5,498,508.34. Following the sale, the insider now directly owns 3,070,099 shares in the company, valued at approximately $230,196,023.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gayle E. Wilson sold 60,000 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $77.92, for a total transaction of $4,675,200.00. Following the sale, the director now owns 182,258 shares in the company, valued at $14,201,543.36. The disclosure for this sale can be found here. Insiders have sold a total of 418,333 shares of company stock worth $32,742,108 over the last 90 days. Corporate insiders own 1.30% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “QUANTRES ASSET MANAGEMENT Ltd Grows Position in Gilead Sciences, Inc. (GILD)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2018/02/14/quantres-asset-management-ltd-grows-position-in-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.